CHMP to Assess Extended Indication of Kineret for COVID-19
Kineret (anakinra) is under evaluation by EMA's CHMP as a treatment for adult COVID-19 patients who are at an increased risk of severe respiratory failure.
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) is assessing data to evaluate whether Kineret (anakinra) can be used as a treatment for adult COVID-19 patients who are at an increased risk of severe respiratory failure.
Kineret is an immunosuppressant that has been authorized for use in the European Union for a number of inflammatory conditions since March 2002. It is believed that the API, anakinra, in Sobi’s Kineret could help reduce the inflammation and tissue damage associated with COVID-19. Anakinra works by blocking the activity of interleukin 1, which is a chemical messenger involved in immune processes that lead to inflammation.
Data from two ongoing clinical studies that are investigating the safety and efficacy of Kineret in adult patients hospitalized with COVID-19 are being evaluated by the CHMP. The committee’s opinion on whether or not Kineret’s indication can be extended will be forwarded to the European Commission, which will issue the final decision on marketing authorization for the European Union.
The outcome of the evaluation, which is expected to be released by October 2021, will be published by EMA.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
